Skip to main content
Neuland Labs

Main navigation

  • CDMO Services
    • Small Molecules
    • Peptides
  • Generic APIs
    • API Products
    • Download Brochure
  • Our Capabilities
    • Chemistry & Reactions
    • Peptide Technologies
    • Lifecycle Management (Phase-Appropriate Development)
    • Quality & Regulatory Compliance
    • Technology Transfer
    • Analytical Expertise
    • Process Safety & Engineering
  • Contact us
User account menu
  • Log in

Breadcrumb

  1. Home

2025

By subhendu, 1 October, 2026

BPS2025

By subhendu, 1 October, 2026

CPHI_Frankfurt2025

By Anonymous (not verified), 19 January, 2026

Analytical Method Validation: Key Parameters & Common Challenges

By Anonymous (not verified), 9 January, 2026

A CDMO’s Guide to Process Development & Scale-Up

By Anonymous (not verified), 9 January, 2026

ESG in Pharma: How CDMOs Drive Sustainable Supply Chains

By Anonymous (not verified), 3 December, 2025

How a Boutique CDMO Differs from a Full-Service CDMO

By Anonymous (not verified), 3 December, 2025

Understanding the Drug Substance Manufacturing Process: Key Steps & CDMO Role

By Anonymous (not verified), 28 November, 2025

What Is Drug Substance Manufacturing and Why Is It Critical in Pharma?

By Anonymous (not verified), 20 November, 2025

Mr. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of Neuland Laboratories, has been elected as Third Vice President to the 2026 Board of Directors of the Drug, Chemical & Associated Technologies Association (DCAT).

By Anonymous (not verified), 4 November, 2025

Neuland Labs Manufacturing Unit-I has been awarded the prestigious Sword of Honour by British Safety Council for excellence in health and safety management systems

Pagination

  • 1
  • Next page
2025
RSS feed
Powered by Drupal